Abstract:Purpose: Both gain-of-function enhancer of zeste homolog 2 (EZH2) mutations and inactivating histone acetyltransferases mutations, such as CREBBP and EP300, have been implicated in the pathogenesis of germinal center (GC)-derived lymphomas. We hypothesized that direct inhibition of EZH2 and histone deacetyltransferase (HDAC) would be synergistic in GC-derived lymphomas. Experimental design: Lymphoma cell lines (n = 21) were exposed to GSK126, an EZH2 inhibitor, and romidepsin, a pan-HDAC inhibitor. Synergy was assessed by excess over bliss. Western blot, mass spectrometry, and coimmunoprecipitation were performed. A SU-DHL-10 xenograft model was utilized to validate in vitro findings. Pretreatment RNA-sequencing of cell lines was performed. MetaVIPER analysis was used to infer protein activity. Results: Exposure to GSK126 and romidepsin demonstrated potent synergy in lymphoma cell lines with EZH2 dysregulation. Combination of romidepsin with other EZH2 inhibitors also demonstrated synergy suggesting a class effect of EZH2 inhibition with romidepsin. Dual inhibition of EZH2 and HDAC led to modulation of acetylation and methylation of H3K27. The synergistic effects of the combination were due to disruption of the PRC2 complex secondary to acetylation of RbAP 46/48. A common basal gene signature was shared among synergistic lymphoma cell lines and was characterized by upregulation in chromatin remodeling genes and transcriptional regulators. This finding was supported by metaVIPER analysis which also revealed that HDAC 1/2 and DNA methyltransferase were associated with EZH2 activation. Conclusions: Inhibition of EZH2 and HDAC is synergistic and leads to the dissociation of PRC2 complex. Our findings support the clinical translation of the combination of EZH2 and HDAC inhibition in EZH2 dysregulated lymphomas.

A Non-Canonical EZH2 Function Sensitizes Solid Tumors to Genotoxic Stress

Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.

Polycomb-independent Activity of EZH2 in Castration Resistant Prostate Cancer

EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells is Polycomb-Independent

EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.

EZH2-mediated development of therapeutic resistance in cancer

Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate Cancer

EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis

A Covalently Bound Inhibitor Triggers EZH2 Degradation Through CHIP-mediated Ubiquitination.

EZH2 Mediated Metabolic Rewiring Promotes Tumor Growth Independently of Histone Methyltransferase Activity in Ovarian Cancer.

EZH1/2 as targets for cancer therapy

Pharmacological Inhibition of EZH2 Combined with DNA‑damaging Agents Interferes with the DNA Damage Response in MM Cells.

Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas

EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer

EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation

Treating human cancer by targeting EZH2

Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma

Integrative Analysis Reveals the Transcriptional Collaboration Between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression